camptothecin has been researched along with Small Cell Lung Carcinoma in 104 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (11.54) | 29.6817 |
| 2010's | 88 (84.62) | 24.3611 |
| 2020's | 4 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Dai, X; Jiang, T; Li, J; Qi, X; Wu, G; Yin, R; Yu, R; Zhang, G | 1 |
| Abbar, B; Bergeret, S; Campedel, L; Foka Tichoue, H; Gougis, P; Hassani, L; Jaffrelot, L; Lassoued, D; Morardet, L; Perrier, A; Roussel-Simonin, C; Spano, JP; Taillade, L; Veyri, M; Vozy, A; Wassermann, J | 1 |
| Akagi, K; Dotsu, Y; Fukuda, M; Gyotoku, H; Hayashi, F; Hisamatsu, Y; Ikeda, T; Kinoshita, A; Morinaga, R; Mukae, H; Nagashima, S; Nakatomi, K; Ogata, R; Ono, S; Senju, H; Shimada, M; Soda, H; Sugasaki, N; Tagawa, R; Takemoto, S; Taniguchi, H; Tomono, H; Umeyama, Y | 1 |
| Bandyopadhyay, A; Behera, D; Sharma, S; Singh, N | 1 |
| Hosomi, Y; Ishii, M; Kato, T; Masuda, N; Minato, K; Misumi, Y; Miura, Y; Nagamata, M; Naoki, K; Ogura, T; Okamoto, H; Okuma, Y; Otani, S; Sasaki, J; Sata, M; Shimokawa, T; Takakura, A; Takata, S; Watanabe, K; Yokoyama, T | 1 |
| Blaydorn, L; Coats, J; Farley, JH; Khemka, V; Lynch, CA; McGahey, K; Niu, J; Sangal, A; Waypa, J; Weiss, GJ | 1 |
| Han, D; Li, S; Ren, X; Shang, W; Sun, L; Wang, G; Xu, L | 1 |
| Bunn, PA; Chan, DC; Drummond, DC; Fitzgerald, JB; Gaddy, DF; Hendriks, BS; Kalra, AV; Klinz, SG; Lee, H; Leonard, SC; Paz, N | 1 |
| Bang, SM; Chang, H; Kim, JH; Kim, JW; Kim, MJ; Kim, SH; Kim, YJ; Lee, JO; Lee, JS; Lee, KW | 1 |
| Li, Q; Sun, L; Wen, F; Zhang, P; Zheng, H; Zhou, J; Zhou, K | 1 |
| Fukui, T; Igawa, S; Katagiri, M; Kubota, M; Kurahayashi, S; Mitsufuji, H; Naoki, K; Nishinarita, N; Okuma, Y; Ono, T; Ozawa, T; Sasaki, J; Shirasawa, M; Sone, H; Sugimoto, A; Sugita, K | 1 |
| Abe, T; Baba, J; Hirata, A; Ichikawa, K; Kikuchi, T; Kondo, R; Koya, T; Makino, M; Maruyama, Y; Sato, K; Shoji, S; Tanaka, H; Tanaka, J; Terada, M; Tsukada, H; Watanabe, S; Yoshizawa, H | 1 |
| Azuma, K; Hoshino, T; Imamura, Y; Ishii, H; Kinoshita, T; Matsuo, N; Naito, Y; Tokito, T; Yamada, K | 1 |
| Chen, Y; Li, Q; Li, R; Ren, X; Xia, S; Xu, F | 1 |
| Lin, B; Shao, L; Song, Z; Zhang, Y | 1 |
| Ghang, HY; Han, JY; Hong, SH; Hwang, JA; Kim, JY; Lee, JS; Lee, YS; Nam, S; Shin, ES; Yoon, SJ | 1 |
| Ando, M; Gemma, A; Hino, M; Kobayashi, K; Kosaihira, S; Kubota, K; Minegishi, Y; Miyanaga, A; Mizutani, H; Nomura, K; Noro, R; Okano, T; Seike, M; Uematsu, K; Yamamoto, K; Yoshimura, A | 1 |
| Chang, J; Cho, BC; Jung, JY; Kim, D; Kim, EY; Kim, GM; Kim, HR; Kim, HS; Kim, JH; Kim, SH; Kim, SK; Kim, YS; Lee, JH; Lim, S; Lim, SM; Park, JS; Park, MS | 1 |
| Ishii, G; Ishikawa, Y; Kenmotsu, H; Nagai, K; Nakajima, R; Niho, S; Noguchi, M; Oshita, F; Sekine, I; Tada, H; Watanabe, S | 1 |
| Levy, B; Saxena, A; Schneider, BJ | 1 |
| Kang, HH; Kim, CH; Kim, JS; Kim, JW; Kim, KH; Kim, SC; Kim, SJ; Kim, YK; Lee, SH; Moon, HS; Shim, BY; Song, JS; Yeo, CD; Yoon, HK | 1 |
| Hao, X; Hu, X; Li, J; Shi, Y; Wang, H; Wang, Y; Xu, J; Yu, S; Zhang, X | 1 |
| Aisner, J; Axelrod, RS; Dahlberg, SE; Gounder, M; Owonikoko, TK; Ramalingam, SS; Rausch, PG; Rubin, EH; Schiller, JH; Wang, XV | 1 |
| Arif, Q; Bharti, A; Brand, TM; Dhanasingh, I; Hembrough, T; Husain, AN; Kanteti, R; Nandi, S; Rolle, CE; Salgia, R; Surati, M; Tretiakova, M; Vokes, EE; Wheeler, DL; Yala, S | 1 |
| Hamilton, G; Klameth, L; Rath, B; Thalhammer, T | 1 |
| Fukita, S; Saitoh, M; Takeda, S; Takeda, T | 1 |
| Ando, M; Atagi, S; Fukuda, H; Hida, T; Ichinose, Y; Kimura, T; Kotani, Y; Minato, K; Nakagawa, K; Nishio, M; Ohe, Y; Saijo, N; Satouchi, M; Shibata, T; Takeda, K; Tamura, T; Yamamoto, N; Yokoyama, A | 1 |
| Yano, S | 1 |
| Goto, K; Matsumoto, S; Morise, M; Niho, S; Ohe, Y; Ohmatsu, H; Umemura, S; Yoh, K | 1 |
| Asamura, H; Fujiwara, Y; Horinouchi, H; Kanda, S; Kitazono, S; Mizugaki, H; Nokihara, H; Tamura, T; Tanaka, A; Tsuta, K; Yagishita, S; Yamamoto, N | 1 |
| Eba, J; Misumi, Y; Nakamura, K; Ohe, Y; Okamoto, H; Shibata, T; Shimokawa, T; Yamamoto, N | 1 |
| Conghua, X; Haifeng, Y; Haiyan, Y; Lei, G; Lulu, M; Tao, L; Yun, F; Zhiyu, H | 1 |
| Fukushima, K; Hayama, Y; Higashiguchi, M; Hirata, H; Hoshino, S; Inoue, K; Kida, H; Kijima, T; Kinehara, Y; Kumanogoh, A; Minami, T; Miyake, K; Morimura, O; Nagatomo, I; Otsuka, T; Takeda, Y; Takeuchi, Y | 1 |
| Li, Y; Lin, X; Lu, S; Zhang, MQ | 1 |
| Chen, Y; Cheng, Y; Jiang, H; Ma, L; Yang, C; Zhu, J | 1 |
| Harada, M; Inoue, A; Ishida, T; Kinoshita, I; Maemondo, M; Mori, Y; Morikawa, N; Nakagawa, T; Nukiwa, T; Oizumi, S; Saito, R; Sugawara, S; Suzuki, T; Taima, K; Watanabe, H | 1 |
| Liang, G; Xu, T; Yang, L; Zhang, F | 1 |
| Inoue, A; Ishimoto, O; Maemondo, M; Nukiwa, T; Sugawara, S | 1 |
| Cai, Q; Shao, N | 1 |
| Alifieris, C; Sitaras, N; Stathopoulos, GP; Trafalis, DT | 1 |
| Chen, L; Chen, Y; Feng, X; Peng, L; Wang, J; Zhong, D | 1 |
| Boumber, Y; Cai, KQ; Deneka, A; Duncan, JS; Duncan, KE; Egleston, BL; Gaponova, AV; Golemis, EA; Khazak, V; Kopp, MC; Kudinov, AE; Nikonova, AS; Ogawa, LS; Proia, DA; Skobeleva, N | 1 |
| Goto, K; Hida, T; Imamura, F; Kiura, K; Kozuki, T; Mori, K; Nakagawa, K; Nishio, M; Ohe, Y; Okamoto, H; Satouchi, M; Sawa, T; Seto, T; Shibata, T; Takahashi, T; Takeda, K; Tamura, T; Tanaka, H; Yoshimura, N | 1 |
| Asao, T; Fujiwara, Y; Goto, Y; Horinouchi, H; Kanda, S; Kitahara, S; Nokihara, H; Ohe, Y; Okuma, HS; Sunami, K; Yamamoto, N | 1 |
| Chen, L; Chen, Y; Zhong, D | 1 |
| Han, JY; Kim, HT; Lee, DH; Lee, JS; Lim, KY; Yoon, SJ | 1 |
| Agelaki, S; Agelidou, A; Chandrinos, V; Christophyllakis, C; Georgoulias, V; Gerogianni, A; Pallis, AG; Papakotoulas, P; Pavlakou, G; Rapti, A; Varthalitis, I | 1 |
| Chen, G; Fehrenbacher, L; Gandara, D; Goldstein, D; Huynh, M; Lara, PN; Lau, D; Russin, M; West, H; Yavorkovsky, LL | 1 |
| Chung, CH; Kim, DM; Kim, HL; Park, CY | 1 |
| Ando, M; Gemma, A; Hino, M; Isobe, K; Kobayashi, K; Kosaihira, S; Kurimoto, F; Miyanaga, A; Mori, G; Nagai, Y; Sakai, H; Uchida, Y; Yamaguchi, T | 1 |
| Carleton, JE; Chansky, K; Crowley, J; Dakhil, SR; Gandara, DR; Jett, J; Kuebler, JP; Langer, CJ; Lara, PN; Lenz, HJ; Natale, R; Redman, MW | 1 |
| Goto, K; Kenmotsu, H; Koga, Y; Kuroda, J; Matsumura, Y; Nagano, T; Nishimura, Y; Nishiwaki, Y; Sugino, T; Yasunaga, M | 1 |
| Kang, JY; Kim, CH; Kim, HK; Kim, JS; Kim, JW; Kim, KH; Kim, SC; Kim, SJ; Kim, YK; Lee, SH; Moon, HS; Shim, BY; Song, JS; Yoon, HK | 1 |
| Harada, M; Isobe, H; Izumi, K; Mino, K; Saito, K; Tanaka, H | 1 |
| Chelis, L; Christophyllakis, Ch; Georgoulias, V; Giassas, S; Kakolyris, S; Kalykaki, A; Kentepozidis, N; Kotsakis, A; Polyzos, A; Vamvakas, L; Vardakis, N; Xenidis, N | 1 |
| Glisson, BS; Johnson, FM | 1 |
| Burris, HA; Farley, C; Greco, FA; Hainsworth, JD; Murphy, PB; Saez, RA; Spigel, DR; Yardley, DA; Zubkus, JD | 1 |
| Bruzzese, F; Budillon, A; Castelli, S; Desideri, A; Di Gennaro, E; Rocco, M | 1 |
| Ahn, JS; Ahn, MJ; Kim, SW; Lee, DH; Lee, JC; Lee, JS; Na, II; Park, K; Ryoo, BY; Suh, C; Yang, SH | 1 |
| Adachi, M; Hirose, T; Nakamura, A; Ohnishi, T; Okuda, K; Yamaoka, T; Yashiki, C | 1 |
| Belani, CP; Evans, T; Foster, J; Gooding, W; Ramalingam, SS; Sulecki, M | 1 |
| Adachi, M; Hirose, T; Kusumoto, S; Nakamura, A; Ohmori, T; Shirai, T; Sugiyama, T; Yashiki, C | 1 |
| Cho, EK; Jung, SH; Kim, YS; Kyung, SY; Lee, JH; Lee, SP; Park, J; Park, JW; Park, SH; Shin, DB; Sym, SJ | 1 |
| Blumenschein, GR; Feng, L; Fossella, FV; Glisson, BS; Johnson, FM; Karp, DD; Peeples, BO; Stewart, DJ; Uyeki, J; William, WN | 1 |
| Cardenal, F; Cisar, L; Domine, M; Gorbunova, V; Moiseyenko, V; Soria, JC; Szczesna, A; Thomas, M; Zatloukal, P; Zhang, X | 1 |
| Aizawa, H; Ichiki, M; Inoue, Y; Nakamura, M; Saitsu, H; Sakata, S; Tokito, T; Wada, Y | 1 |
| Adachi, M; Hirose, T; Kusumoto, S; Ohmori, T; Ohnishi, T; Okuda, K; Shirai, T; Sugiyama, T; Yamaoka, T | 1 |
| Charpidou, A; Gkiozos, I; Makrilia, N; Stratakos, G; Syrigos, K; Tsagouli, S; Tsimpoukis, S; Vassias, A | 1 |
| Ebi, N; Goto, I; Imamura, F; Iwamoto, Y; Kobayashi, M; Matsui, K; Nakagawa, K; Oizumi, S; Saito, H; Saka, H; Sawa, T; Seki, N; Shibata, K; Takeda, K | 1 |
| Chen, W; Gadgeel, SM; Kalemkerian, GP; Kraut, MJ; Ramnath, N; Ruckdeschel, JC; Schneider, BJ; Worden, FP; Wozniak, AJ; Zhang, X | 1 |
| Bao, ZZ; Forootan, SS; Foster, CS; Gosney, JR; Kamalian, L; Ke, Y; Zhang, Y | 1 |
| Chansky, K; Crowley, J; Fukuda, H; Gandara, DR; Lara, PN; Natale, R; Redman, MW; Saijo, N; Shibata, T; Tamura, T | 1 |
| Georgoulias, V; Giassas, S; Gioulbasanis, I; Kalbakis, K; Kontopodis, E; Samonis, G; Vardakis, N; Varthalitis, I; Xenidis, N; Ziras, N | 1 |
| Kang, HH; Kim, CH; Kim, HK; Kim, JS; Kim, JW; Kim, KH; Kim, SC; Kim, SJ; Kim, YK; Lee, SH; Moon, HS; Rhee, CK; Shim, BY; Song, JS; Sun, DS; Yoon, HK | 1 |
| Ikeda, S; Inagaki, M; Suzuki, K; Takabe, K | 1 |
| dos Santos, LV; Lima, CS; Lima, JP; Sasse, AD; Sasse, EC | 1 |
| El-Hadaad, HA; Halim, AA; Wahba, HA | 1 |
| Guo, S; Liang, Y; Zhou, Q | 1 |
| Binder, D; Caca, K; Eberhardt, WE; Fischer von Weikersthal, L; Fischer, B; Fischer, JR; Gauler, TC; Hortig, P; Kaufmann, C; Keilholz, U; Link, H; Martus, P; Schmittel, A; Sebastian, M | 1 |
| Adachi, M; Hirose, T; Kusumoto, S; Murata, Y; Nakashima, M; Ohmori, T; Okuda, K; Shirai, T; Sugiyama, T; Yamaoka, T | 1 |
| Han, JY; Kim, HT; Lee, JS; Lim, KY; Yu, SY; Yun, T | 1 |
| Huang, XE; Li, C; Li, Y | 1 |
| Amin, NP; Camidge, DR; Gaspar, LE; Kavanagh, B; Miften, M; Raben, D; Rochford, N; Thornton, D | 1 |
| Devore, RF; Horn, L; Johnson, D; Laskin, J; Sandler, A; Shyr, Y; Wolff, S; Zhao, Z | 1 |
| Altinbas, M; Camci, C; Dikilitas, M; Kalender, ME; Ozkan, M; Sevinc, A | 1 |
| Ng, RC; Tantisattamo, E | 1 |
| Gen, R; Inoue, N; Nakajima, H; Shibuya, Y; Shikama, Y; Tanzawa, S | 1 |
| Hotta, K; Kiura, K; Matsumura, T; Takigawa, N; Taniguchi, A; Tanimoto, M | 1 |
| Daimon, T; Fujita, Y; Fukushima, M; Furuse, K; Kawahara, M; Komuta, K; Kubo, A; Mio, T; Mishima, M; Sasaki, Y | 1 |
| Jin, S; Shao, N; Zhu, W | 1 |
| Cho, YJ; Duk Lee, J; Go, SI; Hwang, YS; Jeong, YY; Kim, DC; Kim, HC; Ko, GH; Lee, GW; Lee, JH; Lee, JS; Oh, S; Yang, JW | 1 |
| Iyoda, A; Jiang, SX; Kageyama, T; Masuda, N; Matsumoto, T; Nagashio, R; Ryuge, S; Saegusa, M; Sato, Y; Satoh, Y | 1 |
| Guan, QL; Jiang, L; Mi, DH; Wang, J; Yang, KH | 1 |
| Burris, HA; Eakle, JF; Greco, FA; Hainsworth, JD; Lubiner, ET; Quinn, R; Rubin, MS; Shipley, D; Spigel, DR; Thompson, DS | 1 |
| Bradbury, J; Cave, J; Crabb, SJ; Johnson, PW; Muthuramalingam, SR; Nolan, L; Ottensmeier, C; Selman, D | 1 |
| Kenmotsu, Y; Kondo, T; Murakami, S; Ohe, M; Oshita, F; Saito, H; Sugiura, M; Yamada, K | 1 |
| Fukuda, M; Hayashi, N; Ikeda, T; Izumikawa, K; Kinoshita, A; Kohno, S; Nakamura, Y; Oka, M; Soda, H; Soejima, Y; Takatani, H; Tsukamoto, K; Yamaguchi, H | 1 |
| Ando, M; Gemma, A; Hino, M; Kobayashi, K; Kosaihira, S; Minegishi, Y; Miyanaga, A; Mizutani, H; Nomura, K; Noro, R; Okano, T; Seike, M; Yoshimura, A | 1 |
| Harada, D; Ichihara, E; Kiura, K; Kubo, T; Ninomiya, T; Ochi, N; Osawa, M; Takigawa, N; Tanimoto, M; Yamane, H | 1 |
| Kondo, T; Murakami, S; Oshita, F; Saito, H; Sugiura, M; Yamada, K | 1 |
| Ansari, RH; Atkins, JN; Bogart, JA; Green, MR; Hodgson, LD; Kelley, MJ; Pang, H; Vokes, EE | 1 |
| Herbst, RS; Isobe, T; Itasaka, S; Jacoby, JJ; Koo, PJ; Morgensztern, D; O'Reilly, MS; Onn, A; Shibuya, K; Shintani, T; Wu, W | 1 |
| Behera, D; Das, A; Madan, K; Singh, N | 1 |
| Akamatsu, H; Endo, M; Kenmotsu, H; Murakami, H; Naito, T; Nakajima, T; Nakamura, Y; Ono, A; Shukuya, T; Takahashi, T; Tsuya, A; Wakuda, K; Yamamoto, N | 1 |
11 review(s) available for camptothecin and Small Cell Lung Carcinoma
| Article | Year |
|---|---|
Comparison of irinotecan/platinum versus etoposide/platinum chemotherapy for extensive-stage small cell lung cancer: A meta-analysis.
Topics: Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Diarrhea; Etoposide; Fatigue; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Nausea; Neoplasm Staging; Neutropenia; Odds Ratio; Proportional Hazards Models; Small Cell Lung Carcinoma; Thrombocytopenia; Vomiting | 2017 |
Irinotecan-platinum combination therapy for previously untreated extensive-stage small cell lung cancer patients: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Etoposide; Female; Humans; Irinotecan; Male; Platinum; Proportional Hazards Models; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma | 2018 |
Systemic therapy for small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Etoposide; Humans; Irinotecan; Lung Neoplasms; Platinum; Recurrence; Small Cell Lung Carcinoma | 2013 |
[Programs for continuing medical education: B session; 4. Progress in lung cancer therapy].
Topics: Anaplastic Lymphoma Kinase; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cisplatin; Crizotinib; Drug Discovery; Education, Medical, Continuing; Erlotinib Hydrochloride; Etoposide; Gefitinib; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Molecular Targeted Therapy; Pemetrexed; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Small Cell Lung Carcinoma | 2014 |
[First-line Chemotherapy for Extensive-disease Small Cell Lung Cancer:
A Network Meta-analysis].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Network Meta-Analysis; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma | 2016 |
Comparing the adverse effects of platinum in combination with etoposide or irinotecan in previously untreated small-cell lung cancer patients with extensive disease: A network meta-analyses.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug-Related Side Effects and Adverse Reactions; Etoposide; Humans; Irinotecan; Network Meta-Analysis; Platinum; Small Cell Lung Carcinoma | 2017 |
Camptothecins compared with etoposide in combination with platinum analog in extensive stage small cell lung cancer: systematic review with meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Etoposide; Humans; Lung Neoplasms; Neoplasm Staging; Small Cell Lung Carcinoma | 2010 |
Complement and correction for meta-analysis of patients with extensive-stage small cell lung cancer managed with irinotecan/cisplatin versus etoposide/cisplatin as first-line chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome | 2011 |
Dual paraneoplastic syndromes: small cell lung carcinoma-related oncogenic osteomalacia, and syndrome of inappropriate antidiuretic hormone secretion: report of a case and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Diabetes Mellitus, Type 2; Fatal Outcome; Gout; Humans; Hyperlipidemias; Hypertension; Hypophosphatemia; Inappropriate ADH Syndrome; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Osteomalacia; Paraneoplastic Syndromes; Risk Factors; Small Cell Lung Carcinoma | 2011 |
An updated meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Etoposide; Humans; Irinotecan; Lung Neoplasms; Prognosis; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Survival Rate | 2012 |
Cisplatin plus etoposide versus other platin-based regimens for patients with extensive small-cell lung cancer: a systematic review and meta-analysis of randomised, controlled trials.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; Cost-Benefit Analysis; Cyclophosphamide; Drug Therapy, Combination; Epirubicin; Etoposide; Humans; Irinotecan; Lung Neoplasms; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Treatment Outcome | 2012 |
47 trial(s) available for camptothecin and Small Cell Lung Carcinoma
| Article | Year |
|---|---|
Phase II study of IRInotecan treatment after COmbined chemo-immunotherapy for extensive-stage small cell lung cancer: Protocol of IRICO study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Disease Progression; Etoposide; Humans; Immunotherapy; Irinotecan; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum; Small Cell Lung Carcinoma | 2023 |
Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease small-cell lung cancer (LD-SCLC): TORG 0604.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemoradiotherapy; Disease-Free Survival; Female; Humans; Induction Chemotherapy; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Small Cell Lung Carcinoma | 2017 |
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Drug Eruptions; Fatigue; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasms; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Sarcoma; Small Cell Lung Carcinoma; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting | 2017 |
Cost-effectiveness analysis of sensitive relapsed small-cell lung cancer based on JCOG0605 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Cost-Benefit Analysis; Etoposide; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Neoplasm Recurrence, Local; Prognosis; Quality-Adjusted Life Years; Small Cell Lung Carcinoma; Survival Rate; Topotecan | 2018 |
A Phase II Study of Irinotecan for Patients with Previously Treated Small-Cell Lung Cancer.
Topics: Aged; Anorexia; Antineoplastic Agents, Phytogenic; Camptothecin; Chemotherapy-Induced Febrile Neutropenia; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Hyponatremia; Irinotecan; Lung Neoplasms; Male; Middle Aged; Response Evaluation Criteria in Solid Tumors; Retreatment; Small Cell Lung Carcinoma; Survival Rate; Thrombocytopenia | 2018 |
Alternating chemotherapy with amrubicin plus cisplatin and weekly administration of irinotecan plus cisplatin for extensive-stage small cell lung cancer.
Topics: Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma | 2013 |
Phase II study of camtobell inj. (belotecan) in combination with cisplatin in patients with previously untreated, extensive stage small cell lung cancer.
Topics: Adult; Aged; Camptothecin; Cisplatin; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Small Cell Lung Carcinoma; Young Adult | 2013 |
Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Small Cell Lung Carcinoma; Survival Rate; Young Adult | 2013 |
A multicenter phase II study of belotecan, a new camptothecin analogue, in elderly patients with previously untreated, extensive-stage small cell lung cancer.
Topics: Aged; Aged, 80 and over; Camptothecin; Disease Progression; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Neoplasm Staging; Small Cell Lung Carcinoma; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome | 2013 |
E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Small Cell Lung Carcinoma; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 2014 |
Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma; Survival Analysis; Treatment Outcome | 2014 |
A Phase II/III study comparing carboplatin and irinotecan with carboplatin and etoposide for the treatment of elderly patients with extensive-disease small-cell lung cancer (JCOG1201).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Patient Selection; Small Cell Lung Carcinoma; Survival Analysis; Treatment Outcome | 2015 |
Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Retreatment; Small Cell Lung Carcinoma; Survival Rate | 2015 |
Weekly irinotecan combined with carboplatin for patients with small-cell lung cancer: A phase I study.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Diarrhea; Feasibility Studies; Febrile Neutropenia; Female; Humans; Hypokalemia; Hyponatremia; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Small Cell Lung Carcinoma; Thrombocytopenia; Time Factors; Treatment Outcome; Vomiting | 2015 |
Phase II study of bevacizumab plus irinotecan on the treatment of relapsed resistant small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Recurrence; Small Cell Lung Carcinoma | 2016 |
Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Topotecan | 2016 |
Randomized phase II study of maintenance irinotecan therapy versus observation following induction chemotherapy with irinotecan and cisplatin in extensive disease small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Remission Induction; Small Cell Lung Carcinoma; Survival Rate | 2008 |
A multicenter randomized phase II study of the irinotecan/gemcitabine doublet versus irinotecan monotherapy in previously treated patients with extensive stage small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Small Cell Lung Carcinoma | 2009 |
Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma; Survival Rate | 2009 |
Phase II study of nimustine hydrochloride (ACNU) plus paclitaxel for refractory small cell lung cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nimustine; Paclitaxel; Small Cell Lung Carcinoma; Survival Analysis | 2009 |
Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cisplatin; Diarrhea; Etoposide; Female; Glucuronosyltransferase; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neutropenia; Pharmacogenetics; Polymorphism, Single Nucleotide; Risk Factors; Small Cell Lung Carcinoma | 2009 |
A multicenter phase II study of belotecan, new camptothecin analogue, in patients with previously untreated extensive stage disease small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Disease Progression; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Small Cell Lung Carcinoma; Survival Analysis; Topoisomerase I Inhibitors | 2010 |
Etoposide plus cisplatin followed by concurrent chemo-radiotherapy and irinotecan plus cisplatin for patients with limited-stage small cell lung cancer: A multicenter phase II study.
Topics: Aged; Camptothecin; Cisplatin; Drug Therapy, Combination; Etoposide; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Radiotherapy, Adjuvant; Small Cell Lung Carcinoma | 2010 |
Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Camptothecin; Carboplatin; Female; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome | 2009 |
Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy-naive patients with extensive-disease small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Small Cell Lung Carcinoma | 2010 |
Phase 2 study of irinotecan and paclitaxel in patients with recurrent or refractory small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Recurrence; Retreatment; Small Cell Lung Carcinoma | 2010 |
Irinotecan plus carboplatin in patients with extensive-disease small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Camptothecin; Carboplatin; Disease Progression; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Small Cell Lung Carcinoma; Treatment Outcome | 2011 |
Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Small Cell Lung Carcinoma | 2010 |
A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Female; Humans; International Agencies; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Small Cell Lung Carcinoma; Survival Rate; Young Adult | 2010 |
Triplet combination of carboplatin, irinotecan, and etoposide in the first-line treatment of extensive small-cell lung cancer: a single-institution phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma; Treatment Outcome | 2010 |
Phase II study of sequential triplet chemotherapy, irinotecan and cisplatin followed by amrubicin, in patients with extensive-stage small cell lung cancer: West Japan Thoracic Oncology Group Study 0301.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Camptothecin; Cisplatin; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Camptothecin; Cisplatin; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Remission Induction; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome | 2010 |
Α multicenter phase II study of pegylated liposomal doxorubicin in combination with irinotecan as second-line treatment of patients with refractory small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Doxorubicin; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Polyethylene Glycols; Small Cell Lung Carcinoma; Treatment Outcome | 2011 |
A multicenter phase II study of belotecan, a new camptothecin analogue, as a second-line therapy in patients with small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma; Survival Analysis; Topoisomerase I Inhibitors; Treatment Outcome | 2011 |
Irinotecan plus cisplatin chemotherapy followed by concurrent thoracic irradiation with low-dose weekly cisplatin for limited-disease small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Induction Chemotherapy; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Radiotherapy; Small Cell Lung Carcinoma | 2012 |
A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Disease-Free Survival; Etoposide; Female; Germany; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma | 2011 |
Phase II trial of the combination of carboplatin and irinotecan in elderly patients with small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Disease-Free Survival; Female; Humans; Irinotecan; Lung Neoplasms; Male; Medical Oncology; Safety; Small Cell Lung Carcinoma; Time Factors; Treatment Outcome | 2011 |
A phase 2 study of irinotecan, cisplatin, and simvastatin for untreated extensive-disease small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Female; Humans; Irinotecan; Lipids; Lipoproteins; Lung Neoplasms; Male; Middle Aged; Simvastatin; Small Cell Lung Carcinoma; Smoking | 2011 |
Phase II trial of irinotecan plus nedaplatin (INP) in treating patients with extensive stage small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome | 2011 |
A phase II study of carboplatin and irinotecan in extensive stage small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Small Cell Lung Carcinoma | 2011 |
A phase I study of amrubicin and fixed dose of irinotecan (CPT-11) in relapsed small cell lung cancer: Japan multinational trial organization LC0303.
Topics: Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Follow-Up Studies; Humans; International Agencies; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Small Cell Lung Carcinoma; Survival Rate | 2012 |
Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Disease Progression; Female; Humans; Indoles; Induction Chemotherapy; Irinotecan; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Staging; Pyrroles; Small Cell Lung Carcinoma; Sunitinib; Treatment Outcome | 2012 |
A phase I clinical trial of irinotecan and carboplatin in patients with extensive stage small cell lung cancer.
Topics: Adult; Antineoplastic Agents; Area Under Curve; Camptothecin; Carboplatin; Diarrhea; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Sepsis; Small Cell Lung Carcinoma; Thrombosis | 2012 |
Phase II study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome | 2012 |
Combination chemotherapy of alternating etoposide and carboplatin with weekly administration of irinotecan and cisplatin in extensive-stage small-cell lung cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Severity of Illness Index; Small Cell Lung Carcinoma; Thrombocytopenia; Treatment Outcome | 2012 |
Phase II study of nedaplatin and irinotecan in patients with extensive small-cell lung cancer.
Topics: Aged; Camptothecin; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Small Cell Lung Carcinoma | 2013 |
Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemoradiotherapy; Cisplatin; Confidence Intervals; Dehydration; Disease-Free Survival; Dose Fractionation, Radiation; Esophagitis; Etoposide; Female; Humans; Induction Chemotherapy; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Small Cell Lung Carcinoma | 2013 |
46 other study(ies) available for camptothecin and Small Cell Lung Carcinoma
| Article | Year |
|---|---|
Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Humans; Irinotecan; Lung Neoplasms; Small Cell Lung Carcinoma | 2022 |
FOLFIRI in advanced platinum-resistant/refractory small-cell lung cancer: a retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Humans; Lung Neoplasms; Platinum; Retrospective Studies; Small Cell Lung Carcinoma; Treatment Outcome | 2023 |
UGT1A1 Gene Polymorphisms in Patients with Small Cell Lung Cancer Treated with Irinotecan-Platinum Doublet Chemotherapy and Their Association with Gastrointestinal Toxicity and Overall Survival.
Topics: Camptothecin; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Platinum; Polymorphism, Genetic; Prospective Studies; Small Cell Lung Carcinoma | 2021 |
Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; DNA Topoisomerases, Type I; Female; Humans; Irinotecan; Liposomes; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Random Allocation; Small Cell Lung Carcinoma; Topoisomerase I Inhibitors; Topotecan; Xenograft Model Antitumor Assays | 2017 |
Paclitaxel as third-line chemotherapy for small cell lung cancer failing both etoposide- and camptothecin-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Paclitaxel; Retrospective Studies; Small Cell Lung Carcinoma; Treatment Outcome | 2017 |
Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status.
Topics: Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Disease-Free Survival; Etoposide; Female; Health Status; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Thrombocytopenia | 2018 |
Rechallenge treatment with a platinum-based regimen in patients with sensitive relapsed small-cell lung cancer.
Topics: Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Paclitaxel; Recurrence; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate | 2018 |
Single-agent chemotherapy compared with combination chemotherapy as second-line treatment in extensive-stage small cell lung cancer: a retrospective analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Platinum; Prognosis; Retrospective Studies; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Taxoids; Topotecan | 2013 |
A genome-wide association study of survival in small-cell lung cancer patients treated with irinotecan plus cisplatin chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Data Interpretation, Statistical; Disease-Free Survival; Female; Genome-Wide Association Study; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Predictive Value of Tests; Prospective Studies; Small Cell Lung Carcinoma | 2014 |
[A retrospective study of the efficacy and toxicity of irinotecan in combination with nedaplatin versus irinotecan in combination with cisplatin as salvage
treatment in refractory or relapsed small cell lung cancer].
Topics: Adult; Aged; Camptothecin; Cisplatin; Drug Therapy, Combination; Female; Humans; Irinotecan; Middle Aged; Organoplatinum Compounds; Retrospective Studies; Salvage Therapy; Small Cell Lung Carcinoma | 2013 |
Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer.
Topics: Camptothecin; Carcinoma, Small Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Topoisomerases, Type I; Gene Dosage; Gene Expression Regulation, Neoplastic; Humans; Indoles; Irinotecan; Middle Aged; Piperazines; Proto-Oncogene Proteins c-met; Signal Transduction; Small Cell Lung Carcinoma; Sulfonamides; Topoisomerase I Inhibitors | 2014 |
Synergism of cyclin-dependent kinase inhibitors with camptothecin derivatives in small cell lung cancer cell lines.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cyclin-Dependent Kinases; Drug Synergism; Enzyme Inhibitors; Humans; Irinotecan; Small Cell Lung Carcinoma; Topotecan | 2014 |
Small cell carcinoma presenting with massive pleural spread mimicking malignant pleural mesothelioma.
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; Diagnosis, Differential; Fatal Outcome; Humans; Irinotecan; Male; Mesothelioma; Neoplasm Recurrence, Local; Pleural Effusion, Malignant; Pleural Neoplasms; Small Cell Lung Carcinoma | 2014 |
Low-dose irinotecan as a second-line chemotherapy for recurrent small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Medical Records; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neutropenia; Retrospective Studies; Severity of Illness Index; Small Cell Lung Carcinoma; Treatment Outcome; Vomiting | 2014 |
Adjuvant chemotherapy in patients with completely resected small cell lung cancer: a retrospective analysis of 26 consecutive cases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Small Cell Lung Carcinoma; Treatment Outcome | 2014 |
Uridine diphosphate glucuronide transferase 1A1FNx0128 gene polymorphism and the toxicity of irinotecan in recurrent and refractory small cell lung cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Polymorphism, Genetic; Promoter Regions, Genetic; Small Cell Lung Carcinoma; Young Adult | 2014 |
Favorable response to trastuzumab plus irinotecan combination therapy in two patients with HER2-positive relapsed small-cell lung cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Female; Humans; Immunohistochemistry; Irinotecan; Lung Neoplasms; Male; Neoplasm Metastasis; Receptor, ErbB-2; Small Cell Lung Carcinoma; Tomography, X-Ray Computed; Trastuzumab; Treatment Outcome | 2015 |
Irinotecan as a second-line chemotherapy for small cell lung cancer: a systemic analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Small Cell Lung Carcinoma | 2015 |
[Association of UGT1A1 (*28, *60 and * 93) polymorphism with the adverse reactions of irinotecan chemotherapy in extensive stage small cell lung cancer].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia; Polymorphism, Genetic; Promoter Regions, Genetic; Prospective Studies; Retrospective Studies; Small Cell Lung Carcinoma | 2015 |
Prognosis of small cell lung cancer patients with diabetes treated with metformin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Case-Control Studies; Chemotherapy, Adjuvant; Cohort Studies; Diabetes Mellitus, Type 2; Etoposide; Female; Humans; Hypoglycemic Agents; Irinotecan; Lung Neoplasms; Male; Metformin; Middle Aged; Multivariate Analysis; Platinum Compounds; Pneumonectomy; Prognosis; Proportional Hazards Models; Retrospective Studies; Small Cell Lung Carcinoma | 2015 |
High pretreatment neutrophil-lymphocyte ratio predicts recurrence and poor prognosis for combined small cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Camptothecin; Carcinoma, Large Cell; Carcinoma, Squamous Cell; Cohort Studies; Disease-Free Survival; Female; Humans; Irinotecan; Leukocyte Count; Lung Neoplasms; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Complex and Mixed; Neutrophils; Platelet Count; Platinum Compounds; Pneumonectomy; Prognosis; Radiotherapy; Retrospective Studies; Small Cell Lung Carcinoma | 2015 |
A Novel HSP90 Inhibitor-Drug Conjugate to SN38 Is Highly Effective in Small Cell Lung Cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Carboplatin; Cell Cycle Checkpoints; Cell Line, Tumor; DNA Damage; Drug Delivery Systems; Drug Synergism; Female; HSP90 Heat-Shock Proteins; Humans; Irinotecan; Lung Neoplasms; Mice; Mice, SCID; Resorcinols; Signal Transduction; Small Cell Lung Carcinoma; Xenograft Model Antitumor Assays | 2016 |
Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Young Adult | 2017 |
Successful treatment of small-cell lung cancer with irinotecan in a hemodialysis patient with end-stage renal disease.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Disease-Free Survival; Follow-Up Studies; Humans; Irinotecan; Kidney Failure, Chronic; Lung Neoplasms; Male; Middle Aged; Renal Dialysis; Small Cell Lung Carcinoma; Topoisomerase I Inhibitors | 2009 |
Antitumor activity of NK012 combined with cisplatin against small cell lung cancer and intestinal mucosal changes in tumor-bearing mouse after treatment.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Humans; Intestinal Mucosa; Irinotecan; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Small Cell Lung Carcinoma; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2009 |
[Assessment of total bilirubin or SN-38/SN-38G ratio as a predictor of severe irinotecan toxicity].
Topics: Aged; Antineoplastic Agents, Phytogenic; Bilirubin; Camptothecin; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Female; Glucuronates; Humans; Individuality; Irinotecan; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma | 2009 |
Chemotherapy: Irinotecan or etoposide as front-line therapy for SCLC?
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Camptothecin; Carboplatin; Cisplatin; Clinical Trials, Phase III as Topic; Diarrhea; Drug Therapy; Drug Therapy, Combination; Enzyme Inhibitors; Ethnicity; Etoposide; Female; Follow-Up Studies; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Male; Neutropenia; Polymorphism, Genetic; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Survival Analysis; Therapeutic Equivalency; Time Factors; Treatment Outcome | 2009 |
Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; DNA Damage; DNA Topoisomerases, Type I; Drug Synergism; Histone Deacetylases; Humans; Hydroxamic Acids; Lung Neoplasms; Reactive Oxygen Species; Small Cell Lung Carcinoma; Topoisomerase I Inhibitors; Topotecan; Vorinostat | 2009 |
[Chemotherapy-induced myelosuppression and treatment efficacy in extensive-stage small cell lung cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Camptothecin; Carboplatin; Cisplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma | 2009 |
[Chemotherapy-induced myelosuppression and treatment efficacy in limited-stage disease small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Camptothecin; Etoposide; Female; Granulocyte Precursor Cells; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Platinum Compounds; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate | 2010 |
[A case of small cell lung cancer (extensive disease) with liver metastasis acquiring stable disease by hepatic arterial infusion chemotherapy].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Small Cell Lung Carcinoma | 2010 |
The UGT1A1*28 genotype and the toxicity of low-dose irinotecan in patients with advanced lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Genotype; Glucuronosyltransferase; Heterozygote; Homozygote; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Polymorphism, Genetic; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma | 2010 |
Inhibition of tumourigenicity of small cell lung cancer cells by suppressing Id3 expression.
Topics: Animals; Base Sequence; Camptothecin; Cell Growth Processes; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Differentiation Proteins; Lung Neoplasms; Mice; Mice, Nude; Molecular Sequence Data; Neoplasm Proteins; RNA, Small Interfering; Small Cell Lung Carcinoma; Transfection | 2010 |
Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma; Treatment Outcome | 2010 |
Expression of phosphorylated Akt in patients with small cell carcinoma of the lung indicates good prognosis.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Immunohistochemistry; Irinotecan; Kaplan-Meier Estimate; Lung; Lung Neoplasms; Male; Middle Aged; Phosphorylation; Polymorphism, Genetic; Prognosis; Proto-Oncogene Proteins c-akt; Small Cell Lung Carcinoma; Treatment Outcome | 2010 |
Impact of induction chemotherapy on estimated risk of radiation pneumonitis in small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiation Pneumonitis; Radiotherapy, Conformal; Retrospective Studies; Risk Assessment; Small Cell Lung Carcinoma; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Irinotecan as a second-line monotherapy for small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; Disease Progression; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome | 2011 |
[CPT-11 chemotherapy for a hemodialysis patient with small-cell lung cancer].
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase I as Topic; Humans; Irinotecan; Kidney Failure, Chronic; Lung Neoplasms; Male; Renal Dialysis; Small Cell Lung Carcinoma | 2011 |
[A relapse of small-cell lung cancer ten years after concomitant chemoradiotherapy followed by high-dose chemotherapy with autologous peripheral blood stem cell transfusion].
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Chemoradiotherapy; Cisplatin; Humans; Irinotecan; Lung Neoplasms; Male; Peripheral Blood Stem Cell Transplantation; Recurrence; Small Cell Lung Carcinoma; Time Factors | 2011 |
Hypoxia-inducible factor-1α and excision repair cross-complementing 1 in patients with small cell lung cancer who received front-line platinum-based chemotherapy: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Brain Neoplasms; Camptothecin; Carboplatin; Cisplatin; DNA-Binding Proteins; Endonucleases; Etoposide; Female; Follow-Up Studies; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoenzyme Techniques; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate | 2012 |
HADHA is a potential predictor of response to platinum-based chemotherapy for lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Electrophoresis, Gel, Two-Dimensional; Etoposide; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Mitochondrial Trifunctional Protein; Mitochondrial Trifunctional Protein, alpha Subunit; Multienzyme Complexes; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Small Cell Lung Carcinoma; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tumor Cells, Cultured | 2011 |
Nedaplatin and irinotecan for patients with recurrent small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Recurrence; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate | 2012 |
Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy.
Topics: AC133 Antigen; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Animals; Anthracyclines; Antigens, CD; Biomarkers, Tumor; Camptothecin; Cell Cycle; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Glycoproteins; Humans; Irinotecan; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Paclitaxel; Peptides; Receptors, Urokinase Plasminogen Activator; Retinal Dehydrogenase; RNA, Messenger; Small Cell Lung Carcinoma | 2013 |
Evaluation of novel orthotopic nude mouse models for human small-cell lung cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Proliferation; Cisplatin; Etoposide; Humans; Irinotecan; Lung Neoplasms; Mice; Mice, Nude; Necrosis; Paclitaxel; Small Cell Lung Carcinoma; Tumor Cells, Cultured | 2013 |
Pleural tuberculosis following lung cancer chemotherapy: a report of two cases proven pathologically by pleural biopsy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antitubercular Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Small Cell Lung Carcinoma; Tuberculosis, Pleural | 2013 |
Efficacy of rechallenge chemotherapy in patients with sensitive relapsed small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Cohort Studies; Etoposide; Female; Humans; Induction Chemotherapy; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Small Cell Lung Carcinoma; Time Factors; Topotecan; Treatment Outcome | 2015 |